Sometimes in business, you just have to write a check to make a problem disappear. Moderna Inc. (MRNA) did exactly that, and its investors are cheering.

The company's shares were up sharply in Wednesday's premarket after it announced a settlement agreement with Arbutus Biopharma Corporation (ABUS) and Roivant Inc.'s (ROIV) Genevant Sciences. The price tag? A cool $950 million, paid in a lump sum later this year.

Think of it as a very expensive parking ticket for using someone else's patented technology in its COVID-19 vaccine, Spikevax, and its mRESVIA product. The deal resolves all related litigation, which is the kind of legal uncertainty that keeps CFOs up at night.

The Fine Print on a Billion-Dollar Deal

Here's the interesting part: the bill might not be fully paid. Moderna may still have to fork over an additional $1.3 billion, but that depends on the outcome of a separate legal appeal about government-contractor immunity. It's a bit like settling a lawsuit but leaving a tip jar on the counter just in case.

The company noted that if it ends up paying that full $1.3 billion on top of the initial $950 million, it would be the largest disclosed patent settlement in the pharmaceutical industry and the second largest in any industry. That's a record you don't really want to set.

For CEO Stéphane Bancel, the value is in clarity. "Resolving this legacy matter allows the company to concentrate on its near-term future," he said. In other words, they can stop worrying about lawyers and start worrying about making money again.

His plan is ambitious: "In 2026, we will return to revenue growth and end the year with a strong balance sheet, with more than $5 billion in liquidity, as we drive toward breakeven in 2028." The company expects to end 2026 with $4.5 billion to $5 billion in cash, settlement costs notwithstanding.

Why Investors Are Breathing a Sigh of Relief

From the market's reaction, you'd think Moderna got a discount. And in a way, it did. The settlement value was "better than feared," as the saying goes.

Analyst Myles Minter from William Blair pointed out that investors had been contemplating a much scarier scenario: Moderna being on the hook for close to $5 billion in projected liability. A judgment of that size, Minter noted, "could raise potential liquidity concerns." A $950 million check (with a possible $1.3 billion chaser) looks a lot more manageable by comparison.

The takeaway from analysts is that the legal overhang is now gone. Minter sees Moderna moving past it, with "certainty that it is well funded through multiple late-stage oncology readouts expected in 2026." William Blair reiterated its Market Perform rating on the stock.

One Lawsuit Down, But the Legal Drama Isn't Over

Clearing this hurdle doesn't mean Moderna's legal team can take a vacation. In February, BioNTech SE (BNTX) filed a patent infringement lawsuit, alleging that Moderna's next-generation COVID-19 shot, mNEXSPIKE, uses its proprietary tech. So, the patent wars in the mRNA space are very much alive.

How's the Business Doing, Anyway?

Amid all the legal news, it's easy to forget the company still has to sell products. Its latest earnings provided a mixed but slightly positive picture.

For the fourth quarter, Moderna reported a loss of $2.11 per share. That beat the expected loss of $2.59 and was better than the $2.91 loss a year ago. Sales came in at $678 million, topping expectations of $626.1 million. So, while it's still losing money, it's losing less than feared and selling more than expected—a small win in the tough post-pandemic vaccine market.

The Stock's Technical Picture

All this news is pushing the stock higher. It was up 8.85% at $54.24 in premarket trading, knocking on the door of its 52-week high of $55.20.

The technicals show short-term strength: the stock is trading 4.5% above its 20-day simple moving average and 5.2% above its 100-day average. Over the past year, shares have increased significantly and are positioned much closer to their 52-week highs than lows.

The analyst consensus remains cautious but with some bullish outliers. The stock carries a Hold rating with an average price target of $34.40. Recent moves show a split: Piper Sandler is very bullish with an Overweight rating and a $69 target (raised in late February), while Goldman Sachs (Neutral, $41 target) and RBC Capital (Sector Perform, $30 target) are more measured.

For now, Moderna has bought itself some peace. It paid a hefty price, but for investors worried about a legal black hole swallowing the company's cash, $950 million might just look like money well spent.